公开(公告)号：US20230227463A1

公开(公告)日：2023-07-20

申请号：US18176850

申请日：2023-03-01

申请人： Ayman Allian ,  Jayanthy Jayanth ,  Mohamed-Eslam F. Mohamed ,  Mathew M. Mulhern ,  Fredrik Lars Nordstrom ,  Ahmed A. Othman ,  Michael J. Rozema ,  Lakshmi Bhagavatula ,  Patrick J. Marroum ,  Peter T. Mayer ,  Ahmad Y. Sheikh ,  Thomas B. Borchardt ,  Ben Klünder

发明人： Ayman Allian ,  Jayanthy Jayanth ,  Mohamed-Eslam F. Mohamed ,  Mathew M. Mulhern ,  Fredrik Lars Nordstrom ,  Ahmed A. Othman ,  Michael J. Rozema ,  Lakshmi Bhagavatula ,  Patrick J. Marroum ,  Peter T. Mayer ,  Ahmad Y. Sheikh ,  Thomas B. Borchardt ,  Ben Klünder

IPC分类号： C07D487/14 ,  A61K9/00 ,  A61K47/12 ,  A61K47/38 ,  A61K31/4985

CPC分类号： C07D487/14 ,  A61K9/0053 ,  A61K47/12 ,  A61K47/38 ,  A61K31/4985 ,  C07B2200/13

摘要： The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and various spondyloarthritic conditions, including types of axial spondyloarthritis (axSpA)), kits, methods of synthesis, and products-by-process. In various aspects, provided are methods for treating active non-radiographic axSpA (nr-axSpA) and methods for treating active ankylosing spondylitis (AS).